硬骨素因其在控制骨形成方面的作用而最受认可;然而,它也表达在心中,主动脉,冠状动脉,和外周动脉。人体研究已将高循环硬化素水平与不同心血管疾病(CVD)的存在相关联。替代CVD标记,和一些人群心血管事件的高风险。然而,这仍然是一个科学辩论的问题,因为研究之间的结果非常不同。在本次审查中,我们分析了血清硬化蛋白水平与CVD和/或心血管死亡率之间的关系.为此,我们进行了一项范围审查,其中选择了测量患者血清硬化蛋白水平和心血管风险的文章.11篇文章回答了研究问题;在这些文章中,8/11评估了硬化蛋白和CVD之间的关联,其中4/8发现了正相关,2/8发现了负关联,和2/8发现变量之间没有关联。研究中纳入的五篇(5/11)文章评估了心血管死亡率,其中3/5发现了正相关,1/5发现了负关联,和1/5发现变量之间没有关联。总之,由于结果的异质性,我们没有发现足够的结果来证明硬化蛋白水平升高与普通人群中CVD和/或心血管死亡率的发展之间存在关联.然而,在特定人群中,硬化素水平升高似乎是心血管事件发生和心血管死亡的危险因素.该领域的进一步研究将有助于解决本范围审查中发现的一些不一致之处,并允许将来使用硬化素测量作为预防和诊断CVD和/或心血管死亡率的策略。
Sclerostin is most recognized for its role in controlling bone formation; however, it is also expressed in the heart, aorta, coronary, and peripheral arteries. Human studies have associated high circulating
sclerostin levels with the presence of different cardiovascular diseases (CVD), surrogate CVD markers, and a high risk of cardiovascular events in some populations. However, this is still a matter of scientific debate, as the results have been very heterogeneous among studies. In the present
review, the association between serum
sclerostin levels and CVD and/or cardiovascular mortality was analyzed. For this purpose, a scoping
review was performed in which articles measuring serum
sclerostin levels and cardiovascular risk in patients were selected. Eleven articles answered the research question; of these articles, 8/11 evaluated the association between sclerostin and CVD, of which 4/8 found a positive association, 2/8 found a negative association, and 2/8 found no association between variables. Five (5/11) of the articles included in the study evaluated cardiovascular mortality, of which 3/5 found a positive association, 1/5 found a negative association, and 1/5 found no association between variables. In conclusion, we did not find sufficient results to be able to demonstrate an association between elevated sclerostin levels and the development of CVD and/or cardiovascular mortality in the general population due to heterogeneity in the results. However, there seems to be a tendency to consider increased sclerostin levels as a risk factor for both the development of cardiovascular events and cardiovascular mortality in specific populations. Further studies in this field will help to solve some of the inconsistencies found during this scoping
review and allow for the future use of sclerostin measurement as a strategy in the prevention and diagnosis of CVD and/or cardiovascular mortality.